Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Identification of mutations associated with acquired resistance to sunitinib in renal cell-cancer.

Elgendy M, Fusco JP, Segura V, Lozano MD, Minucci S, Echeveste JI, Gurpide A, Andueza M, Melero I, Sanmamed MF, Ruiz MR, Calvo A, Pascual JI, Velis JM, Miñana B, Valle RD, Pio R, Agorreta J, Abengozar M, Colecchia M, Brich S, Renne SL, Guruceaga E, Patiño-García A, Perez-Gracia JL.

Int J Cancer. 2019 Mar 8. doi: 10.1002/ijc.32256. [Epub ahead of print]

PMID:
30848481
2.

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.

Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L.

Nat Med. 2019 Mar 4. doi: 10.1038/s41591-019-0374-x. [Epub ahead of print]

PMID:
30833750
3.

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS.

Clin Cancer Res. 2019 Mar 1. pii: clincanres.1538.2018. doi: 10.1158/1078-0432.CCR-18-1538. [Epub ahead of print]

PMID:
30824587
4.

The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.

Lee JW, Zhang Y, Eoh KJ, Sharma R, Sanmamed MF, Wu J, Choi J, Park HS, Iwasaki A, Kaftan E, Chen L, Papadimitrakopoulou V, Herbst RS, Koo JS.

J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30111-X. doi: 10.1016/j.jtho.2019.02.004. [Epub ahead of print]

PMID:
30771521
5.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I.

Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11.

PMID:
30742120
6.

Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?

Perez-Gracia JL, Sanmamed MF, Melero I.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S356-S357. doi: 10.21037/tlcr.2018.10.12. No abstract available.

7.

TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.

Rodríguez-Ruiz ME, Rodríguez I, Mayorga L, Labiano T, Barbes B, Etxeberria I, Ponz-Sarvise M, Azpilikueta A, Bolaños E, Sanmamed MF, Berraondo P, Calvo FA, Barcelos-Hoff MH, Perez-Gracia JL, Melero I.

Mol Cancer Ther. 2019 Mar;18(3):621-631. doi: 10.1158/1535-7163.MCT-18-0558. Epub 2019 Jan 25.

PMID:
30683810
8.

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Sanmamed MF, Chen L.

Cell. 2019 Jan 24;176(3):677. doi: 10.1016/j.cell.2019.01.008. No abstract available.

PMID:
30682374
9.

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.

Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L.

Cell. 2019 Jan 10;176(1-2):334-347.e12. doi: 10.1016/j.cell.2018.11.010. Epub 2018 Dec 20.

PMID:
30580966
10.

Immunodivergence in Metastatic Colorectal Cancer.

de Andrea CE, Schalper KA, Sanmamed MF, Melero I.

Cancer Cell. 2018 Dec 10;34(6):876-878. doi: 10.1016/j.ccell.2018.11.012.

PMID:
30537510
11.

Cytokines in clinical cancer immunotherapy.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I.

Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Review.

PMID:
30413827
12.

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Sanmamed MF, Chen L.

Cell. 2018 Oct 4;175(2):313-326. doi: 10.1016/j.cell.2018.09.035. Review. Erratum in: Cell. 2019 Jan 24;176(3):677.

PMID:
30290139
13.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.

Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA.

Nat Commun. 2018 Aug 10;9(1):3196. doi: 10.1038/s41467-018-05032-8.

14.

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.

Fusco JP, Pita G, Pajares MJ, Andueza MP, Patiño-García A, de-Torres JP, Gurpide A, Zulueta J, Alonso R, Alvarez N, Pio R, Melero I, Sanmamed MF, Rodriguez Ruiz M, Gil-Bazo I, Lopez-Picazo JM, Casanova C, Baz Davila R, Agudo A, Lozano MD, Gonzalez A, Sala N, Ardanaz E, Benitez J, Montuenga L, Gonzalez-Neira A, Perez-Gracia JL.

Cancer Med. 2018 May 15. doi: 10.1002/cam4.1500. [Epub ahead of print]

15.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
16.

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.

Chester C, Sanmamed MF, Wang J, Melero I.

Blood. 2018 Jan 4;131(1):49-57. doi: 10.1182/blood-2017-06-741041. Epub 2017 Nov 8. Review.

17.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

18.

Interleukin-8 in cancer pathogenesis, treatment and follow-up.

Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I.

Cancer Treat Rev. 2017 Nov;60:24-31. doi: 10.1016/j.ctrv.2017.08.004. Epub 2017 Aug 31. Review.

PMID:
28866366
19.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I.

Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.

20.

Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours.

Sanmamed MF, Esteban E, Uriol E, Zarate R, Capelan M, Muriel C, Crespo G, Berros JP, Pardo-Coto P, Perez Q, Alvarez-Fernández C, Jiménez Fonseca P, Luque M, Astudillo A.

J Transl Med. 2017 Mar 20;15(1):62. doi: 10.1186/s12967-017-1162-3.

21.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

22.

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I.

Cancer Res. 2016 Oct 15;76(20):5994-6005. Epub 2016 Aug 22.

23.

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.

Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Jan 15;23(2):370-378. doi: 10.1158/1078-0432.CCR-16-0150. Epub 2016 Jul 20.

24.

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).

Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, Garasa S, Fusco JP, Aznar A, Inogés S, De Pizzol M, Allegretti M, Medina-Echeverz J, Berraondo P, Perez-Gracia JL, Melero I.

Clin Cancer Res. 2016 Aug 1;22(15):3924-36. doi: 10.1158/1078-0432.CCR-15-2463. Epub 2016 Mar 8.

25.

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.

Sanmamed MF, Chester C, Melero I, Kohrt H.

Ann Oncol. 2016 Jul;27(7):1190-8. doi: 10.1093/annonc/mdw041. Epub 2016 Feb 23. Review.

PMID:
26912558
26.

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.

Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I.

Semin Oncol. 2015 Aug;42(4):640-55. doi: 10.1053/j.seminoncol.2015.05.014. Epub 2015 Jun 11. Review.

PMID:
26320067
27.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I.

Cancer Res. 2015 Sep 1;75(17):3466-78. doi: 10.1158/0008-5472.CAN-14-3510. Epub 2015 Jun 25.

28.

Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.

Melero I, Quetglas JI, Reboredo M, Dubrot J, Rodriguez-Madoz JR, Mancheño U, Casales E, Riezu-Boj JI, Ruiz-Guillen M, Ochoa MC, Sanmamed MF, Thieblemont N, Smerdou C, Hervas-Stubbs S.

Cancer Res. 2015 Feb 1;75(3):497-507. doi: 10.1158/0008-5472.CAN-13-3356. Epub 2014 Dec 19.

29.

Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.

Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Zárate R, Lozano MD, Zubiri L, Perez-Gracia JL, Martín-Algarra S, González A.

Clin Chem. 2015 Jan;61(1):297-304. doi: 10.1373/clinchem.2014.230235. Epub 2014 Nov 19.

30.

Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins.

Sanmamed MF, Carranza-Rua O, Alfaro C, Oñate C, Martín-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, Muñoz-Calleja C, Rodríguez-Ruiz M, Sangro B, López-Picazo JM, Rizzo M, Mazzolini G, Pascual JI, Andueza MP, Perez-Gracia JL, Melero I.

Clin Cancer Res. 2014 Nov 15;20(22):5697-707. doi: 10.1158/1078-0432.CCR-13-3203. Epub 2014 Sep 15.

31.

Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.

Sanmamed MF, Chen L.

Cancer J. 2014 Jul-Aug;20(4):256-61. doi: 10.1097/PPO.0000000000000061. Review.

32.

Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma.

Alegre E, Sanmamed MF, Rodriguez C, Carranza O, Martín-Algarra S, González A.

Arch Pathol Lab Med. 2014 Jun;138(6):828-32. doi: 10.5858/arpa.2013-0134-OA.

PMID:
24878024
33.

Orchestrating immune check-point blockade for cancer immunotherapy in combinations.

Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I.

Curr Opin Immunol. 2014 Apr;27:89-97. doi: 10.1016/j.coi.2014.01.002. Epub 2014 Jan 28. Review.

PMID:
24485523
34.

Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.

Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Lozano MD, Echeveste JI, Pérez Gracia JL, Alegre E, Carranza O, Zubiri L, Martín-Algarra S, González A.

Clin Chim Acta. 2014 Feb 15;429:168-74. doi: 10.1016/j.cca.2013.11.034. Epub 2013 Dec 9.

PMID:
24333389
35.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

36.

Agonist antibodies to TNFR molecules that costimulate T and NK cells.

Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD.

Clin Cancer Res. 2013 Mar 1;19(5):1044-53. doi: 10.1158/1078-0432.CCR-12-2065. Erratum in: Clin Cancer Res. 2013 Apr 1;19(7):1913.

37.

Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism.

Bustos M, Dubrot J, Martinez-Anso E, Larequi E, Castaño D, Palazon A, Belza I, Sanmamed MF, Perez-Gracia JL, Ortiz de Solorzano C, Alfaro C, Melero I.

Oncoimmunology. 2012 Dec 1;1(9):1527-1536.

38.

The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies.

Mazzolini G, Ochoa MC, Morales-Kastresana A, Sanmamed MF, Melero I.

Immunotherapy. 2012 Nov;4(11):1081-5. doi: 10.2217/imt.12.99. No abstract available.

PMID:
23194355
39.

Interleukin-15 in gene therapy of cancer.

Ochoa MC, Mazzolini G, Hervas-Stubbs S, de Sanmamed MF, Berraondo P, Melero I.

Curr Gene Ther. 2013 Feb;13(1):15-30. Review.

PMID:
23157547
40.

Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.

Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, Melero I.

Mol Ther. 2012 Sep;20(9):1664-75. doi: 10.1038/mt.2012.56. Epub 2012 Jun 26.

41.

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.

Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, de Landázuri MO, Jure-Kunkel M, Aragonés J, Melero I.

Cancer Discov. 2012 Jul;2(7):608-23. doi: 10.1158/2159-8290.CD-11-0314. Epub 2012 Jun 19.

42.

Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes.

Alfaro C, Suarez N, Oñate C, Perez-Gracia JL, Martinez-Forero I, Hervas-Stubbs S, Rodriguez I, Perez G, Bolaños E, Palazon A, Sanmamed MF, Morales-Kastresana A, Gonzalez A, Melero I.

PLoS One. 2011;6(12):e29300. doi: 10.1371/journal.pone.0029300. Epub 2011 Dec 20.

43.

Direct effects of type I interferons on cells of the immune system.

Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I.

Clin Cancer Res. 2011 May 1;17(9):2619-27. doi: 10.1158/1078-0432.CCR-10-1114. Epub 2011 Mar 3. Review.

Supplemental Content

Loading ...
Support Center